On Friday 13 January, the ECDC updated its assessment of the SARS-CoV-2 variant of interest XBB1.5 and the implication of its spread for the European Union and the European Economic Area (see EUROPE B13095A17).
The ECDC emphasises that, in the context of the XBB.1.5 spread, the vaccines currently authorised in the EU remain effective against severe forms of Covid-19. The ECDC states that there are currently no estimates of vaccine efficacy and that there is evidence of a decrease in...